AG0039KS

Name: 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
Brand: Angene Chemical
SKU: AG0039KS

284461-73-0 | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide

Chemical structure of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide, CAS 284461-73-0

AG0039KS

SDS

COA

TIP This product is typically in stock.Please contact us for quotation.

Request For Quotation

CAS Number	284461-73-0
Catalog Number	AG0039KS(AGN-PC-0R42XI)
Chemical Name	4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
EC Number	608-209-4
IUPAC Name	4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
InChI	InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
InChI Key	MLDQJTXFUGDVEO-UHFFFAOYSA-N
MDL Number	MFCD06411450
Molecular Formula	C21H16ClF3N4O3
Molecular Weight	464.8249
NSC Number	747971
SMILES	ClC1=C(C=C(C=C1)NC(=O)NC1=CC=C(OC2=CC(=NC=C2)C(=O)NC)C=C1)C(F)(F)F
UNII	9ZOQ3TZI87
Synonyms	4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate, BAY 43 9006, BAY 43-9006, BAY 439006, BAY 545 9085, BAY 545-9085, BAY 5459085, BAY 673472, BAY-545-9085, BAY-673472, BAY5459085, Nexavar, sorafenib, Sorafenib N Oxide, sorafenib N-oxide, sorafenib tosylate, Sorafenib, 284461-73-0, Nexavar, BAY 43-9006, 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide, UNII-9ZOQ3TZI87, 4-(4-(3-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)UREIDO)PHENOXY)-N-METHYLPICOLINAMIDE, 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide, N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea, 9ZOQ3TZI87, CHEMBL1336, 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide, 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide, 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE, CHEBI:50924, Sorafenib-d3, MFCD06411450, 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-, BAY-43-9006, Sorafenib (Nexavar), Sorafenib [INN], 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide, sorafenibum, 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, BAX, NSC-724772, BAY-54-9085, NCGC00167488-01, Sorafinib, Sorafenib [USAN:INN:BAN], SR-00000000529, HSDB 8173, 1uwh, 3gcs, 3heg, 4asd, Hit compound, 8, Sorafenib, 4, BAY 439006, BAY43-9006, Kinome_766, SORAFENIB BASE, Sorafenib (USAN/INN), Nexavar (TN) (Bayer), EC 608-209-4, AC1L50CF, SCHEMBL8218, 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate, cid_216239, GTPL5711, QCR-65, DTXSID7041128, BDBM16673, Nexavar\|\|\|BAY 43-9006, SYN1082, MLDQJTXFUGDVEO-UHFFFAOYSA-N, BCPP000064, HMS2043A18, HMS3244A15, HMS3244A16, HMS3244B15, HMS3656N20, K00597a, ACT06732, AOB87782, BCP01767, ZINC1493878, AN-613, BAY439006, CS0056, NSC747971, RS0103, s7397, STK627350, AKOS005560229, AC-1674, ACN-032355, CS-1590, DB00398, MCULE-6112506696, NSC-747971, PB14443, SB19942, SF-0529, BAY-43-0006, KS-0000009E, Sorafenib free base (BAY-43-9006), NCGC00167488-02, NCGC00167488-03, NCGC00167488-04, NCGC00167488-05, NCGC00167488-07, NCGC00167488-14, 100012-18-8, 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide, AK163019, BC679588, EN002709, HY-10201, N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea, SC-19355, AB0019677, AB1004622, LS-186067, LS-187021, LS-187788, AM20090614, FT-0650736, SW202562-4, D08524, J10391, 15216-EP2272827A1, 15216-EP2298778A1, 15216-EP2311840A1, 15216-EP2316832A1, 15216-EP2316833A1, AB00933189-05, AB00933189-06, AB00933189_08, 461S730, I06-0856, Q-201728, SR-00000000529-1, BRD-K23984367-001-01-8, Z89277543, 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl) ureido) phenoxy)-N-methylpicolinamide, 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl) ureido)phenoxy)-N-methylpicolinamide, N-(3-trifluoromethyl-4-chlorophenyl)-N'-(4-(2-methylcarbamoyl pyridin-4-yl)oxyphenyl)urea, 4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N2-methylpyridine-2-carboxamide, 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-picolinamide;tosylic acid, 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-amino]phenoxy}-N-methylpyridine-2-carboxamide, 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methyl-pyridine-2-carboxamide, N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide, Sorafenib tosylate, Xarelto, Sorafenibtosylate, Sorafenib tosilate, Sorafenib N oxide, Sorafenib N-Oxide, Sorafenib (INN), Nexavar (TN), C21H16ClF3N4O3, D0W5HK, Sorafenib (Pan-TK inhibitor), Sorafenib, 98% - 10MG 10mg, 284461-73-0 (free base), CID216239, BAY 545-9085, BAY-545-9085, C21-H16-Cl-F3-N4-O3, BAY 673472, BAY-673472, BAY5459085, CS-O-11744, ND-0224, BAY 43 9006, BAY 5459085, BAY 545 9085, 2161B, A3009, A8245, V0124, C-8800, C471405, 475207-59-1, D000077157, 1130115-44-4, 4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea,

Complexity	646
Compound Is Canonicalized	Yes
Covalently-Bonded Unit Count	1
Defined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Exact Mass	464.086g/mol
Formal Charge	0
Heavy Atom Count	32
Hydrogen Bond Acceptor Count	7
Hydrogen Bond Donor Count	3
Isotope Atom Count	0
Molecular Weight	464.829g/mol
Monoisotopic Mass	464.086g/mol
Rotatable Bond Count	5
Topological Polar Surface Area	92.4A^2
Undefined Atom Stereocenter Count	0
Undefined Bond Stereocenter Count	0
XLogP3	4.1

Related Research Chemicals

CERTIFICATE OF ANALYSIS

Chemical Name:	Batch Number:
Chemical Structure:	CAS Registry No:
	Product ID:
	Manufacture Date:
	Storage Temperature:
	Formula:
	Molecular Weight:
	Quantity:

Analysis Data:

Test:

Result:

Conclusion: The above product meets the specifications of Angene.

Analyst:Chase

Date:

Reviewed by:Jessie

Date:

Angene International Limited

Symbol:
Hazard statements
Precautionary statements